Home > Insider Trading > Filing (0001209191-21-021525)

Filing Details

Accession Number:: 0001209191-21-021525
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-03-17 18:35:34
Reporting Period:: 2021-03-15

Accepted Time:: 2021-03-17 18:35:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1000694	Novavax Inc	NVAX	Biological Products, (No Disgnostic Substances) (2836)	222816046

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1342823	M Gregory Glenn	C/O Novavax, Inc. 21 Firstfield Road Gaithersburg MD 20878	President, R&D	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-03-15	619	$27.00	3,430	No	4	M	Direct
Common Stock	Acquisiton	2021-03-15	868	$27.60	4,298	No	4	M	Direct
Common Stock	Acquisiton	2021-03-15	1,101	$46.00	5,399	No	4	M	Direct
Common Stock	Acquisiton	2021-03-15	3,124	$5.95	8,523	No	4	M	Direct
Common Stock	Disposition	2021-03-15	901	$196.88	7,622	No	4	S	Direct
Common Stock	Disposition	2021-03-15	1,939	$197.87	5,683	No	4	S	Direct
Common Stock	Disposition	2021-03-15	1,490	$199.07	4,193	No	4	S	Direct
Common Stock	Disposition	2021-03-15	1,282	$200.14	2,911	No	4	S	Direct
Common Stock	Disposition	2021-03-15	100	$201.47	2,811	No	4	S	Direct
Common Stock	Acquisiton	2021-03-15	4,819	$217.46	7,630	No	4	M	Direct
Common Stock	Disposition	2021-03-15	132	$217.46	7,498	No	4	D	Direct
Common Stock	Disposition	2021-03-15	2,264	$217.46	5,234	No	4	F	Direct
Common Stock	Disposition	2021-03-17	5	$210.85	5,229	No	4	S	Direct
Common Stock	Disposition	2021-03-17	57	$211.96	5,172	No	4	S	Direct
Common Stock	Disposition	2021-03-17	57	$213.01	5,115	No	4	S	Direct
Common Stock	Disposition	2021-03-17	459	$215.19	4,656	No	4	S	Direct
Common Stock	Disposition	2021-03-17	421	$216.05	4,235	No	4	S	Direct
Common Stock	Disposition	2021-03-17	402	$217.31	3,833	No	4	S	Direct
Common Stock	Disposition	2021-03-17	114	$218.53	3,719	No	4	S	Direct
Common Stock	Disposition	2021-03-17	180	$219.84	3,539	No	4	S	Direct
Common Stock	Disposition	2021-03-17	60	$221.91	3,479	No	4	S	Direct
Common Stock	Disposition	2021-03-17	164	$223.86	3,315	No	4	S	Direct
Common Stock	Disposition	2021-03-17	375	$224.78	2,940	No	4	S	Direct
Common Stock	Disposition	2021-03-17	129	$225.89	2,811	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	D	Direct
No	4	F	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-03-15	619	$0.00	619	$27.00
Common Stock	Stock Option (Right to Buy)	Disposition	2021-03-15	868	$0.00	868	$27.60
Common Stock	Stock Option (Right to Buy)	Disposition	2021-03-15	1,101	$0.00	1,101	$46.00
Common Stock	Stock Option (Right to Buy)	Disposition	2021-03-15	3,124	$0.00	3,124	$5.95
Common Stock	Stock Appreciation Right	Disposition	2021-03-15	4,819	$0.00	4,819	$5.95

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,861	2026-11-14	No	4	M	Direct
6,605	2027-12-15	No	4	M	Direct
16,322	2028-12-13	No	4	M	Direct
68,752	2029-09-26	No	4	M	Direct
56,462	2029-09-26	No	4	M	Direct

Footnotes

The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.27 to $197.23, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.54 to $198.24, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.68 to $199.58, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.84 to $200.65, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reporting person received 2,423 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 132 shares of common stock underlying the stock appreciation rights representing the base value and 2,264 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on March 15, 2021 of $217.46.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.94 to $211.97, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.00 to $213.02, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.73 to $215.70, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.73 to $216.41, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.80 to $217.71, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.37 to $218.68, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.45 to $220.15, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.31 to $224.26, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.37 to $225.26, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.50 to $226.27, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
Vesting of the shares subject to this option grant under the Plan were subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments on the first of each month over the following three (3) years subject to continued employment through such vesting date, and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares vested, if at any time during the four-year period from the November 14, 2016 grant date, the volume-weighted average stock price of Novavax, Inc.'s common stock met or exceeded $80.00, $120.00, or $160.00, respectively, for twenty (20) consecutive trading days. Novavax, Inc.'s common stock did not meet $160.00 for twenty (20) consecutive trading days and therefore 2,918 shares were cancelled.
Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this stock appreciation right grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.